Ultragenyx agrees to sell rare pediatric disease PRV for $203M
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)

